NCT01064349View on ClinicalTrials.gov

Breast Cancer With Over-expression of erbB2-BRAINSTORM

CompletedOBSERVATIONAL
Enrollment

144

Participants

Timeline

Start Date

May 6, 2009

Primary Completion Date

June 3, 2011

Study Completion Date

June 3, 2011

Conditions
Cancer
Interventions
DRUG

Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer

Trastuzumab or Lapatinib

Trial Locations (10)

1101

GSK Investigational Site, Quezon City

1102

GSK Investigational Site, Quezon City

1300

GSK Investigational Site, Pasay

10110

GSK Investigational Site, Bangkok

10310

GSK Investigational Site, Bangkok

10330

GSK Investigational Site, Bangkok

10400

GSK Investigational Site, Bangkok

10700

GSK Investigational Site, Bangkok

50200

GSK Investigational Site, Chiang Mai

119074

GSK Investigational Site, Singapore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY